F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
39 hedge funds and large institutions have $59M invested in F-star Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
19% more capital invested
Capital invested by funds: $49.7M → $59M (+$9.23M)
3% more funds holding
Funds holding: 38 → 39 (+1)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 3 |
Millennium Management
New York
|
+$546K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$502K |
| 5 |
MAM
Morse Asset Management
Darien,
Connecticut
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$999K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$619K |
| 3 |
VV
Verity & Verity
Beaufort,
South Carolina
|
-$289K |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$219K |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$198K |
FSTX Hedge Fund Activity: Q1 2018 in Review
39 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2018, worth a combined $59M — up 19% from $49.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FSTX positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.32M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $999K sold.
- 39 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2018, up from 38 in Q4 2017.
- Funds reported $59M of F-star Therapeutics, Inc. Common Stock stock for Q1 2018, up 19% quarter-over-quarter.
- 6 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2018 and 5 closed out, a net change of +1 holder.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2018 was Adage Capital Partners, an estimated $1.32M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2018 was Sphera Funds Management, an estimated $999K sold.
Based on aggregated 13F filings for Q1 2018.